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The central nervous system (CNS), once viewed as an immune-privileged site protected
by the blood–brain barrier (BBB), is now known to be a dynamic immunological environ-
ment through which immune cells migrate to prevent and respond to events such as
localized infection. During these responses, endogenous glial cells, including astrocytes
and microglia, become highly reactive and may secrete inflammatory mediators that reg-
ulate BBB permeability and recruit additional circulating immune cells. Here, we discuss
the various roles played by astrocytes, microglia, and infiltrating immune cells during host
immunity to non-tumor antigens in the CNS, focusing first on bacterial and viral infec-
tions, and then turning to responses directed against self-antigens in the setting of CNS
autoimmunity.
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INTRODUCTION
The central nervous system (CNS) was previously viewed as an
immune-privileged area, fully isolated from the immune system by
the blood–brain barrier (BBB). In early studies, Ehrlich reported
that while various organs were strongly stained following intra-
venous, intra-arterial, or subcutaneous injection of intravital dyes,
the brain was only weakly stained or not at all (1). Other studies
found that tissue grafts were not rejected when implanted into the
brains of test animals (2), leading to the idea that the CNS was fully
“immune-privileged.” This viewpoint had to be altered, however,
after it was discovered that a graft within the CNS could be rejected
if a second graft was placed subcutaneously into the same animal
(3). This finding clearly demonstrated that foreign antigens are
recognized in the CNS if peripheral priming occurs (3). It is now
accepted that the BBB is a dynamic, interactive, and regulatory tis-
sue interface that allows bi-directional communication between
the CNS and the immune system (4, 5).
The BBB, formed by complex interactions between capillary
endothelial cells (ECs), astrocyte end-feet, pericytes, and microglia
(6, 7), is the largest and most stringent barrier that impedes the
paracellular movement of ions, solutes, proteins, water, and leuko-
cytes into the CNS (8). However, the BBB can also be influenced
by peripheral immune events, creating what has now come to be
known as the neuro-immune axis (4, 9, 10). The neuro-immune
axis is not only responsible for establishing the blood–CNS barrier
at baseline, but it also regulates communication between the CNS
and the immune system during pathological conditions such as
viral or bacterial infections, ischemia, or inflammatory autoim-
mune disorders such as multiple sclerosis (MS) (11). It achieves
this state by responding to secreted factors from both immune and
CNS cells, as well as by regulating the exchange of chemokines,
cytokines, and immune cells between the blood and the CNS (4,
9, 10). Therefore, the original concept of the BBB being a purely
anatomical barrier has now shifted to one where the BBB is consid-
ered a highly reactive interface controlled by signals from ECs, glial
cells, pericytes, and neurons in the CNS, as well as from immune
responses in the periphery (12–21).
STRUCTURAL CHARACTERISTICS OF THE BBB
The BBB is composed of capillary ECs ensheathed by astrocyte
end-feet, pericytes, and microglia (6, 7). Astrocyte end-feet com-
pletely surround the abluminal surface of brain capillaries forming
a layer known as the glial limitans, but direct contact with EC is
inhibited by a dense basement membrane (22). While astrocytes
are necessary to maintain BBB integrity by secreting factors that
alter barrier permeability (6, 23), they are not actually required
to form the BBB, which develops even before these astrocytic
processes are present (24–26). Astrocytes control blood flow to
the CNS by regulating vascular tone through fluctuating calcium
currents (27). Pericytes are essential to barrier formation, as the
BBB is compromised in pericyte-deficient mice (28, 29). These
cells regulate gene expression in EC and induce the polarization
of astrocyte end-feet (28). Microglia play a role at the BBB by reg-
ulating substrate transport across EC and by linking the brain to
systemic immune activity (30).
Blood–brain barrier EC forms a highly sophisticated barrier
via a network of tight junctions (TJ) and adherens junctions (AJ)
(8, 31, 32). The EC of the CNS are unique in that the TJ restrict
the paracellular passage of solutes, have no pinocytic activity, and
have few if any fenestrations (33–39). This causes the BBB to have
high endothelial electrical resistance (40, 41), some 50–100 times
higher than peripheral microvessels (42–44). The TJ are composed
of a parallel network of intramembranous protein strands, com-
posed of claudins, occludin, and zonula occludin (ZO) proteins
(37). Claudins, specifically claudin-3, -4, and -12, compose the TJ
backbone (45–47). Occludin is not required for TJ formation (48);
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instead, it plays a role in “sealing” the junction thereby increasing
electrical resistance (49, 50). CNS microvessel TJ are also abundant
in ZO-2, and to a lesser extent, ZO-1, that are cytoplasmic acces-
sory proteins that serve to anchor the transmembrane proteins of
the TJ to the actin cytoskeleton of the ECs (51, 52).
The choroid plexus (CP) is a villous structure located on the
roof of the four cerebral ventricles where cerebrospinal fluid (CSF)
is actively secreted. The CP is highly vascular and contains the
blood–CSF barrier (BCSFB) (51). Unlike the BBB, however, the
BCSFB arises from cuboidal choroid plexus epithelial cells (CPE)
with a very different TJ structure. The CPE express ZO-1 and ZO-2
in different amounts (51), and have a different claudin signature,
expressing claudin-1, -2, -3, and -11 (51, 53, 54). Furthermore,
capillaries within the CP villi are fenestrated (51, 55, 56), reflected
by a much lower endothelial electrical resistance than the BBB
(57). For these reasons, the BBB is considered more of an absolute
barrier, while the BCSFB may be where most normal immune
surveillance of the CNS occurs (58).
IMMUNE SURVEILLANCE AND INFILTRATION OF THE CNS
It is now accepted there is a constant need for immune surveil-
lance of the normal CNS as part of host defense (11, 59, 60), with
mechanisms present that simultaneously keep excessive inflam-
mation in check (61). To assist in maintaining this control, the
healthy CNS is relatively devoid of antigen-presenting cells (APC),
lacks constitutive human leukocyte antigen (HLA) class I and II
protein expression on parenchymal cells, and does not maintain
typical lymphatic vessels (11). CD4+ T cells, having first encoun-
tered antigens in deep cervical lymph nodes (62), carry out routine
surveillance of the CNS by searching for their cognate antigens pre-
sented by macrophages in the CSF (11, 63). Resting lymphocytes
fail to enter the CNS (64), while activated T cells of all specificities
can traverse the BBB and/or BCSFB (65). Those cells that do not
encounter their cognate antigen within a few hours then circulate
out of the CNS (66, 67).
The first steps of pathogenic neuroinflammation involve
changes at the BBB, including increased production of chemokines
and up-regulation of adhesion molecules by the EC resulting in
leukocytes traversing the BBB and accumulating in the perivas-
cular space of post-capillary venules (11, 68). Even during these
early events, however, cellular recruitment remains tightly con-
trolled as parenchymal lymphocytes express a unique adhesion
molecule profile, different from peripheral T cells (69–71). Once
in the perivascular space, T cells encounter the glial limitans as well
as astrocytes that express and release factors that induce apoptosis
(72), inhibit proliferation (72), induce differentiation into a reg-
ulatory (Treg) phenotype (73). Microglia and neurons also assist
in controlling neuroinflammation. Microglia do so by express-
ing a homolog of the co-stimulatory molecule B7, programed
death protein (PD)-1, which negatively regulates T cell activa-
tion and cytokine production (74). Neurons secrete transforming
growth factor (TGF)-β, exert cell contact-dependent effects that
support the conversion of CD4 T cells to Tregs, and can be
induced to express the PD-1 ligand, PD-L1 (75). Thus, while the
BBB is not the impenetrable barrier it was once thought to be,
CD4+ T cell surveillance of the CNS is still a tightly controlled
process.
HOST IMMUNE RESPONSES TO BACTERIAL INFECTIONS OF
THE CNS
Bacterial infections of the CNS are rare, but often life threat-
ening, events (76). Excluding direct inoculation following CNS
trauma, bacteria typically gain CNS entry following hematoge-
nous dissemination from distant sites (lungs and heart valves) or
by direct extension from parameningeal foci of infection (inner ear
and sinuses). Penetration of the BBB may occur via three poten-
tial mechanisms: (1) direct destruction of capillary ECs (77, 78),
(2) disruption of intercellular TJ and migration in between ECs
(79), and (3) transcytosis via intracellular vesicles directly through
ECs (80). Once inside, numerous innate immune receptors and
pathways are activated (Figure 1).
MICROGLIA
Analogous to peripheral tissues, resident CNS immune cells
known as microglia bear a wide range of innate immune receptors.
Common bacterial motifs, referred to as pathogen associated mol-
ecular patterns (PAMP), are recognized by cognate pattern recog-
nition receptors (PRR), including Toll-like receptors (TLR), on the
surface and in the cytoplasm of microglia, and to a lesser extent, on
astrocytes (81–83). Microglial activation, triggered either by intact
bacteria or bacterial cell wall antigens (84, 85), results in rapid
changes in cellular morphology in vivo (86). Similar to tissue resi-
dent macrophages found in the periphery, microglia can phagocy-
tize bacteria and present bacterial antigens via HLA to infiltrating
CD4 T cells in vivo (84, 87, 88). These cells also rapidly produce
pro-inflammatory cytokines and chemokines that recruit periph-
eral leukocytes to the area of infection and activate astrocytes. For
example, during both experimental Streptococcus pneumoniae and
Staphylococcus aureus infections of the CNS, microglia produce
tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-12, C-X-C
motif ligand (CXCL)1, CXCL2, C-C motif ligand (CCL)2, CCL3,
and CCL5 ex vivo, mediators that recruit neutrophils (CXCL1 and
CXCL2), monocytes (CCL2 and CCL3), and T cells (CCL5) (84, 85,
89–91). These activated microglia also secrete matrix metallopro-
teinases (MMP) that enhance BBB breakdown and facilitate addi-
tional leukocyte extravasation into the CNS (92). Finally, microglia
can have direct bactericidal activity, being capable of producing
reactive oxygen species (ROS), reactive nitrogen intermediates,
and other proteases that kill bacteria in vivo (93–96).
ASTROCYTES
Microglia partner with astrocytes to eliminate infection as quickly
as possible in order to minimize neuronal damage (86, 97, 98).
In the normal CNS, astrocytes contribute to gap junction stabil-
ity of the BBB (99). Their release of pro-inflammatory mediators
such as IL-1β (100, 101), nitric oxide (102), TGF-β (103), and
MMPs (92) in vitro suggest these cells may compromise BBB
integrity in the setting of bacterial infection. Astrocytes are acti-
vated by bacterial PAMP or mediators produced by microglia; this
changes their morphology and further triggers their release of
innate inflammatory mediators both in vitro and in vivo. These
mediators can include complement proteins, IL-1β, IL-6, and
the chemokines, CCL2, CCL3, CXCL1, and CXCL10 (104–111),
which further help recruit neutrophils, monocytes, and T cells. In
response to interferon (IFN)-γ, TNF-α, and/or IL-1β, astrocytes
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FIGURE 1 | Orchestration of the immune response during bacterial
infection of the CNS. In the quiescent CNS (1), bacteria typically gain entry
by transcytosis across the endothelial cells of the BBB, or by passing in
between endothelial cells where tight junctions have been disrupted (2).
Common bacterial motifs (PAMPs) are recognized by pattern recognition
receptors (PRRs) on microglia and astrocytes resulting in their activation. This
causes changes in glial cell morphology, enhanced production of inflammatory
mediators that recruit neutrophils, monocytes, and T cells, and increased
endothelial cell expression of adhesion molecules, including ICAM-1 and
VCAM-1 (3). Circulating neutrophils, monocytes, and T cells then bind and
extravasate into the infected CNS (4). Neutrophils directly phagocytize and kill
bacteria through the release of defensins, lytic enzymes, and anti-microbial
peptides (5). Neutrophils also produce MMPs, IL-6, IL-8, CXCL9, and CXCL10
that further open the BBB and shift the chemotactic profile toward the
recruitment of T cells. Bacterial antigens are presented to T cells by microglia
and/or infiltrating monocytes, transitioning from innate immunity toward an
adaptive immune response (6). Resolution of bacterial infection returns tight
junctions to normal and microglia and astrocytes to a resting state (7).
also up-regulate the cell surface adhesion molecules, intercellular
adhesion molecule (ICAM)-1, and vascular cell adhesion mol-
ecule (VCAM)-1 in vitro (112–116), which would enhance the
infiltration of monocytes and T cells into the CNS in vivo.
NEUTROPHILS
As in the periphery (117, 118), neutrophils are one of the primary
lines of host defense during CNS bacterial infections (112, 119,
120). Studies in knockout mice show that the main chemokines
driving neutrophil recruitment to the CNS are the C-X-C motif
receptor (CXCR)-2 ligands, CXCL1 and CXCL2 (121). Further-
more, CSF samples from patients with bacterial meningitis show
elevated levels of neutrophil attracting chemokines compared to
controls (122, 123). Neutrophils, like microglia, respond to PAMP
through various TLR, and are activated by cytokines such as TNF-α
and IFN-γ in vitro (124). Neutrophils activated in the periph-
ery up-regulate adhesion molecules that enhance their migration
into tissues (125), while BBB EC express E-selectin and P-selectin
during CNS bacterial infection (126), suggesting a mechanism
that allows for the migration of neutrophils during these infec-
tions. Once neutrophils recognize a bacterial pathogen, they can
directly phagocytize these organisms (127), as well as release MMP,
defensins, lytic enzymes, and anti-microbial peptides that aid in
clearing the infection (128). The inflammatory cytokine, TNF-α,
induces neutrophils to produce IL-6, IL-8, CXCL9, and CXCL10
in vivo (129, 130), thereby shifting the chemotactic profile toward
the recruitment of T cells and driving the adaptive immune
response.
T CELLS
Adaptive immune responses are important in fighting CNS bacter-
ial infections (131). During bacterial meningitis, T cell production
of IFN-γ leads to the generation of chemokines that preferen-
tially recruit monocytes and more T cells (132), supporting the
transition from an innate to an adaptive immune response. Fur-
thermore, IFN-γ, potentially made locally by T cells, increases the
antigen-presenting capacity of microglial cells in vitro via up-
regulation of HLA class I and II molecules, the co-stimulatory
molecules, B7-1 and B7-2, and CD40 (133, 134). Bacterial antigen
presentation by microglia activates T cells (135), driving further T
cell proliferation and greater production of IFN-γ.
HOST IMMUNE RESPONSES TO VIRAL INFECTIONS OF THE
CNS
Viruses use a variety of mechanisms to gain entry into the CNS.
In the case of alphaherpesviruses (i.e., herpes simplex virus and
varicella-zoster virus) and rabies virus, infection of peripheral
nerves allows viral particles to travel by anterograde axonal trans-
port into the CNS. Human immunodeficiency virus and human T
cell leukemia virus-I enter the CNS parenchyma by infecting host
immune cells in the periphery, and using them as “Trojan horses”
to carry viral particles across the BBB. Finally, Epstein–Barr virus
and West Nile virus directly infect the ECs of the BBB, resulting in
barrier disruption and enhanced migration of immune cells into
the parenchyma (136).
Because viruses can infect microglia, astrocytes, oligodendro-
cytes, as well as terminally differentiated and non-renewable cells
such as neurons, the ensuing immune response within the CNS
must avoid extensive cytolytic damage of virus-infected target
cells (137). In general, innate anti-viral immunity such as the
generation of type-I IFN occurs very rapidly, while the adaptive
immune response is slower because it must first develop in the
periphery (138). Important components of adaptive anti-viral
immunity involve IFN-γ production by T cells as well as the
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expansion and migration of virus-specific antibody secreting cells
(ASC) (138, 139) (Figure 2).
MICROGLIA, ASTROCYTES, AND OLIGODENDROCYTES
During CNS viral infections, virus-specific PAMP activate indi-
vidual TLR present on microglia, astrocytes, and oligodendro-
cytes. The former two cell populations, in particular, respond
by producing anti-viral and pro-inflammatory mediators. During
experimental mouse hepatitis virus (MHV) infection, astrocytes
and microglia produce both type-I IFN (IFN-α and IFN-β), as well
as IL-6, TNF-α, IL-12, IL-1α, and IL-1β in vivo (140–142). Fur-
thermore, MHV infection triggers MMP-3 and MMP-12 release
from astrocytes and oligodendrocytes (142), which along with
FIGURE 2 | Orchestration of the immune response during viral
infection of the CNS. With the BBB in a resting state (1), viruses can gain
entry into the CNS by infecting peripheral nerves and traveling by
anterograde axonal transport into the CNS, by infecting host immune cells
in the periphery and using these cells as “Trojan horses” to carry them
across the BBB, or by directly infecting BBB endothelial cells (2). Viral
PAMPs then activate microglia, astrocytes, and oligodendrocytes (3).
Microglia and astrocytes produce a range of anti-viral/pro-inflammatory
cytokines, including type-I IFNs, IL-6, TNF-α, IL-12, IL-1α, and IL-1β (3).
Astrocytes also produce MMP-3 and MMP-12 resulting in the up-regulation
of adhesion molecules on endothelial cells (3). Interactions between
adhesion molecules and neutrophils contribute to BBB breakdown via the
production of MMP-9 and the disassembly of the tight junctions (4). DCs
are seen in the CNS within several days and migrate to draining lymph
nodes where they activate and expand virus-specific T cells (5).
Chemokines produced by astrocytes are responsible for recruiting
virus-specific CD4+ and CD8+T cells as well as ASCs to the CNS (6).
CD8+T cells produce IFN-γ and lytic molecules, including granzyme B and
perforin, to eliminate virus from astrocytes, while IFN-γ controls viral
replication in oligodendrocytes (7). Virus-specific antibodies control virus
replication in cells such as neurons via complement–independent,
non-cytolytic mechanisms. These antibodies inhibit virus budding and
replication, viral RNA transcription, and cell-to-cell virus spread.
IL-6 and the up-regulation of adhesion molecules on cerebrovas-
cular endothelium, enhance cellular migration across the BBB
(143). Astrocytes produce CXCL10, CXCL11, and CCL5 in vivo
that recruit virus-specific CD4+ and CD8+ T cells (144–146), as
well as ASC (147, 148), to the CNS to promote viral clearance.
CXCL9 production from microglia is dependent on IFN-γ, while
CXCL10 and CXCL11 are up-regulated by type-I IFN and TNF-α
(149–152).
MYELOID LINEAGE CELLS
Neutrophils and macrophages are recruited to the CNS following
viral infection (153, 154). Thus far, macrophages appear to have
more limited anti-viral activity in the CNS (155), but neutrophils
contribute to the breakdown of the BBB by interacting with EC via
adhesion molecules to promote the disassembly of tight junction
complexes (156). Neutrophils also secrete MMP-9 that degrades
the extracellular matrix and basal lamina of the BBB and further
opens the BBB (157). This has been most clearly demonstrated in
the MHV model, where depletion of MMP-9 inhibited lymphocyte
infiltration into the CNS (157, 158). Dendritic cells (DC) are seen
in the CNS within a few days after CNS viral infection. These cells
rely on the chemokine CCL3 to migrate to cervical lymph nodes
draining the CNS, where they prime virus-specific T cells (159).
T CELLS
In the MHV model, virus-specific CD8+ T cells are detected in
local lymph nodes prior to CNS infiltration and then accumu-
late in the CNS (160). Both CD4+ and CD8+ T cells are in part
recruited to the CNS by the chemokines, CXCL9 and CXCL10,
acting through their cognate receptor, CXCR3 (161–163). T cell
expression of CCR2 and CCR5 likely contribute to CNS recruit-
ment as well (164, 165). The role of CD4+ T cells in this setting
is to support CD8+ T cell function via the production of IFN-γ
(166). CD8+ T cells are the main anti-viral effector cells in the
CNS during infection and are essential for clearing virus from
glial cells (142, 167, 168). CD8+ T cells produce IFN-γ and lytic
molecules, including granzyme B and perforin (169). These lytic
molecules eliminate virally infected astrocytes (170), while IFN-γ
serves to control viral replication in oligodendrocytes (171, 172).
In both the MHV and Sindbis virus (SINV) encephalitis models,
T cells promote B cell proliferation and differentiation (173, 174),
in part by secreting the cytokines, IL-10 and IL-21 (175–177).
B CELLS AND ANTI-VIRAL ANTIBODIES
Virus-specific ASC help control viruses in the CNS through potent
complement-independent, non-cytolytic mechanisms (141, 178–
183). These ASC arise either from ectopic lymphoid follicle-like
structures within the CNS (152) or migrate from cervical lymph
nodes where they have expanded and up-regulated CXCR3 and
CXCR4 on their surface prior to entering the CNS (184). ASC
recruitment to the CNS has been most extensively studied in the
SINV encephalitis model. The initial ASC entering the CNS have
an HLA class II positive,plasmablast-like phenotype,but these cells
gradually lose HLA class II expression and acquire a more plasma
cell-like phenotype (139, 141). Virus-specific antibodies function
to neutralize both extracellular virus as well as virus particles
budding from infected cell membranes. During SINV infection,
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antibodies that bind the E2 viral envelope glycoprotein inhibit
virus replication (185) and prevent viral budding from infected
neurons without actually killing target cells (182, 186). Similarly,
during rabies virus infection, antibodies against the RV glycopro-
tein inhibit viral RNA transcription and prevent cell-to-cell viral
spread (187). Antibodies can also trigger natural killer (NK) cells
and macrophages to induce antibody dependent cell-mediated
cytolysis of virally infected cells (152). Finally, in exchange for
non-cytolytic viral clearance in the acute setting, virus-specific
ASC must persist in the CNS long term to prevent viral reactiva-
tion at a later date since viral RNA is never fully eradicated from
target tissues (139).
HOST IMMUNE RESPONSES TO SELF (MYELIN) ANTIGENS IN
THE CNS
MULTIPLE SCLEROSIS
Multiple sclerosis, an autoimmune disease characterized by infil-
trating immune cells targeting myelin antigens in the CNS, is the
most common cause of neurologic disability in persons younger
than 40 years of age (188). Pathologically, MS lesions are charac-
terized by focal inflammation, demyelination, and axonal damage
(189). MS is a complex disease whose occurrence and progres-
sion are influenced by both genetic (190–192) and environmental
(193, 194) risk factors. Evidence derived from both human genetic
studies and a related mouse model, experimental autoimmune
encephalomyelitis (EAE), suggest that encephalitogenic CD4+ T
cells are primary initiators of disease. Genome-wide association
studies show that MS risk alleles are confined to immune related
genes governing antigen presentation as well as the proliferation
and survival of T cells, including HLA class II (HLA-DRB1*1501),
IL-2R, and IL-7R (190–192). Moreover, EAE in mice is induced
by immunizing animals with various myelin peptides (195), or
via the adoptive transfer of myelin-specific CD4+ T cells, result-
ing in a disease having some clinical and pathological similarities
to human MS (196, 197). In MS patients, CD4+ T cells localize
within CNS lesions present in the brain (198) and spinal cord
(199), and elevated frequencies of myelin-reactive CD4+ T cells
can be found in circulating the blood (200, 201). Although not
described in detail here due to space constraints, many MS lesions
also contain abundant CD8+ T cells whose specificity and role in
disease pathogenesis remain poorly understood. Likewise, thera-
pies targeted specifically at B cells have proven highly effective in
MS patients, highlighting an emerging role for this cell type in
both relapsing and progressive forms of disease.
ROLE OF CD4+ T CELLS IN AUTOIMMUNE INFLAMMATION OF THE CNS
During both MS and EAE, self-reactive T cells are likely activated
in the periphery (189), where they undergo initial differentiation
and expansion (124). Upon entry into the CNS, these cells are
reactivated by myelin epitopes presented by an as of yet uniden-
tified local DC (202, 203). Production of cytokines such as IFN-γ
and TNF-α from activated CD4+ T cells results in local activa-
tion of resting microglia, leading to the up-regulation of HLA
class I and II as well as co-stimulatory molecules (B7-1, B7-2,
and CD40) on the surface of these cells (133, 134, 204, 205).
These activated microglia are capable of serving as APC for infil-
trating myelin-specific CD4+ T cells in vivo thus sustaining this
pathogenic local T cell response (97). Production of cytokines,
chemokines, and MMPs by microglia (206) facilitate local inflam-
mation by causing BBB breakdown and recruiting more immune
cells into the CNS. These include circulating monocytes capable of
differentiating into inflammatory DC and macrophages upon tis-
sue entry (207), culminating in demyelination (124). Furthermore,
microglial production of IL-23 and IL-1β promotes granulocyte
macrophage colony-stimulating factor (GM-CSF) secretion by
CD4+ T cells (208). GM-CSF has been shown in EAE to pro-
mote CNS inflammation by mobilizing Ly6Chi monocytes from
the bone marrow into the periphery, thereby increasing the num-
ber of circulating monocytes available for recruitment to the CNS
(207). GM-CSF can also increase HLA class II expression and pro-
inflammatory cytokine production by microglia, macrophages,
and DC in vitro (209, 210). IL-17 producing T cells have been
detected within CNS lesions during both EAE and MS (211, 212).
IL-17 promotes brain inflammation, inducing the production of
pro-inflammatory cytokines, TNF-α, IL-6, and IL-1β most proba-
bly from astrocytes, microglia, or macrophages. It also stimulates
the release of chemokines responsible for recruiting neutrophils to
the CNS, particularly CXCL1 and CXCL2 (213, 214). Finally, IL-17
can disrupt TJ in the BBB, allowing further migration of CD4+ T
cells to the CNS (212, 215).
ROLE OF GLIAL CELLS IN AUTOIMMUNE INFLAMMATION OF THE CNS
Microglia
Microglia play important roles in augmenting CNS inflamma-
tion, demyelination, and neuronal damage in both EAE and MS
(67, 216–218). Activation of microglia occurs rapidly following
the induction of EAE and results in the release of cytokines,
chemokines, ROS, and tissue-degrading MMP (206). One media-
tor, TNF-like weak inducer of apoptosis (TWEAK), triggers prolif-
eration, angiogenesis, inflammation, is associated with extensive
myelin loss, and induces astrocyte cell death during MS (219).
IL-17 produced by microglia (220) worsens brain inflammation
by stimulating GM-CSF production, as well as increasing IL-
6, inflammatory proteins, nitric oxide, and adhesion molecule
expression by macrophages. Moreover, expression of myeloperox-
idase (MPO) and ROS by microglia results in direct myelin degra-
dation and neuronal damage (216, 218). Paradoxically, microglia
also can play a neuroprotective role during CNS autoimmunity.
These cells can promote remyelination, protect neurons, and sup-
press the adaptive immune response within the CNS (221, 222).
Within MS lesions, microglia and macrophages express the neu-
rotrophic factors, nerve growth factor (NGF), and brain-derived
neurotrophic factor (BDNF), supporting neuronal survival (220,
223, 224). Furthermore, microglia secrete the anti-inflammatory
cytokines, IL-10 and TGF-β, and express the inhibitory receptor,
PD-L1, responsible for inhibiting T cell proliferation and cytokine
production (74, 225).
Astrocytes
Astrocytes are a major source of CCL2 and CXCL10 in the CNS,
regulating the migration of monocytes into the brain (CCL2) and
microglia into the lesion site (CXCL10) (111, 226–228). One study
suggested these cells play a more prominent role in regulating the
recruitment of peripheral monocytes into the CNS (229). CXCL12,
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a chemokine that induces the expression of CXCL8 and CCL2, is
also expressed by astrocytes in MS lesions (230). CXCL12 can be
cleaved by MMP-2, also expressed by astrocytes in MS and EAE,
into a neurotoxic peptide that causes further neuronal damage
(231). Similar to microglia, astrocytes also play a protective role
during MS and EAE. Homeostatic astrocyte functions include
buffering potassium, removing extracellular glutamate that can
accumulate to toxic levels, adjusting water balance, and control-
ling synaptic activity and blood flow in the CNS (8). These cells
are also able to produce neurotrophins and the anti-inflammatory
cytokine, IL-10 (232).
CONCLUSION
The vast complexity of cellular interconnections within the CNS,
and the non-renewable nature of many neural cells, mandate that
some local immune responses be tightly controlled while others
(i.e., cytolytic ones) be excluded to the fullest extent possible.
The BBB is a dynamic and highly regulated tissue interface that
helps make the CNS a unique immunological environment. It
responds to signals from both neurons and glial cells on one
side while simultaneously being able to sample immunological
events passing through intravascular compartments. Immune cells
perform normal surveillance of the CNS by searching for anti-
gens previously encountered in extraneural sites such as the deep
cervical lymph nodes. Pathological conditions such as infections
caused by viruses or bacteria elicit changes at the BBB, includ-
ing the up-regulation of a unique subset of adhesion molecules
as well as heightened release of chemokines by ECs. Mediators
produced by astrocytes and microglia further increase BBB perme-
ability and recruit additional circulating leukocytes into the CNS.
The ensuing immune response must then be tightly controlled
in order to avoid collateral tissue damage. As such, astrocytes
and microglia maintain mechanisms to dampen inflammatory
responses. In some settings, immune cells such as ASC persist long
term within the CNS to prevent viral reactivation. When nor-
mal control mechanisms fail, neuroinflammatory diseases such
as MS can result. For this reason alone, it is imperative that
the complexity of immune reactions within the CNS be better
understood.
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